Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detail on financial results, material corporate events, and key regulatory milestones for Syndax’s oncology-focused business.
Recent Forms 8-K filed by Syndax include items on quarterly and year-to-date financial results, where the company furnishes press releases and presentations summarizing revenue from Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), research and development spending, and operating expense trends. Other 8-K filings document significant events such as U.S. Food and Drug Administration approval of Revuforj for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation, as well as board-level changes.
For investors analyzing SNDX, these SEC documents complement earnings press releases and conference call materials by providing standardized, time-stamped records of the company’s disclosures. They help clarify how Syndax reports collaboration revenue from its agreement with Incyte for Niktimvo, how it describes its cash position and funding horizon, and how it characterizes the impact of regulatory approvals on its business.
On Stock Titan, Syndax filings are updated as new documents are posted to EDGAR, and AI-powered tools can assist in navigating complex language, highlighting items related to product approvals, clinical milestones, financial condition, and governance. Users can review 8-Ks for material events, and, where available, refer to 10-K and 10-Q filings for broader discussions of risk factors, pipeline programs, and the company’s description of its commercial-stage biopharmaceutical operations.
Syndax Pharmaceuticals director Martin H. Huber Jr. received an award of 24,000 shares in the form of restricted stock units on February 4, 2026, at a price of $0 per share. After this grant, he beneficially owns 103,000 shares of common stock in direct form.
The restricted stock units vest one year from the grant date. The underlying shares will not be delivered and cannot be transferred or sold until the earlier of a separation from service, death, disability, or a change in control of the company.
Syndax Pharmaceuticals granted equity awards to its Head of R&D and Chief Medical Officer, Nicholas A.J. Botwood, as part of his compensation on 02/04/2026. He received 24,000 time-based RSUs, each representing one share of common stock, which vest in three equal annual installments over three years, contingent on continued service.
He also received 36,000 performance-based RSUs, with shares issuable only if pre-established performance metrics approved by the Compensation Committee are achieved and he remains in service. In addition, he was granted 144,700 stock options with an exercise price of $20.43 per share, vesting in equal monthly installments over four years. All reported common stock awards were acquired at $0 per share, reflecting non-cash equity compensation.
Syndax Pharmaceuticals director Dennis Podlesak reported an equity award on this Form 4. On February 4, 2026, he was granted 48,000 restricted stock units at a price of $0 per share. These units vest one year from the grant date.
The shares underlying the restricted stock units will only be delivered, and may not be transferred or sold, until the earlier of a separation from service, death, disability, or a change in control. After this grant, Podlesak beneficially owns 239,763 shares of common stock, held directly.
Syndax Pharmaceuticals director Aleksandra Rizo reported a grant of 24,000 shares of common stock on February 4, 2026. The award was made at a price of $0 per share and increased her beneficial ownership to 49,000 shares held directly.
The grant represents restricted stock units that vest one year from the grant date. The underlying shares will only be delivered, and therefore cannot be transferred or sold, until the earlier of a separation from service, death, disability, or a change in control.
Syndax Pharmaceuticals director Keith Katkin reported an equity award of 24,000 shares of common stock in the form of restricted stock units (RSUs) on February 4, 2026. The award was granted at a price of $0 per share, increasing his beneficial ownership to 124,000 shares held directly.
The RSUs vest one year from the grant date. However, the underlying shares will not be delivered and cannot be transferred or sold until the earlier of a separation from service, death, disability, or a change in control, creating a deferral feature on actual share delivery.
Syndax Pharmaceuticals director receives equity award. Director Pierre Legault was granted 24,000 shares of Syndax Pharmaceuticals common stock on February 4, 2026 as a stock award priced at $0 per share, increasing his beneficial ownership to 114,000 shares held directly.
The award is in the form of restricted stock units that vest one year from the grant date. The underlying shares cannot be delivered, transferred, or sold until vesting and the earlier of separation from service, death, disability, or a change in control.
A shareholder filed a notice of proposed sale under Rule 144 to sell 7,412 shares of common stock through Fidelity Brokerage Services LLC on or about 02/06/2026 on the NASDAQ. The filing reports an aggregate market value of $152,836.18 for these securities, compared with 86,914,838 shares outstanding for the issuer. The shares to be sold were acquired on 02/05/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 02/05/2026. The signer represents they are not aware of undisclosed material adverse information about the issuer’s operations.
SNDX has a Form 144 notice covering a proposed sale of 2,082 shares of its common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of 42,931.05.
The shares were acquired on 02/05/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 02/05/2026. The filing notes that 86,914,838 shares of common stock are outstanding and includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership of Syndax Pharmaceuticals common stock as of 12/31/2025. Vanguard reports beneficial ownership of 6,230,334 shares, representing 7.16% of the outstanding common stock. It has no sole voting or dispositive power, with 702,989 shares subject to shared voting power and 6,230,334 shares subject to shared dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Syndax. Vanguard notes that its clients have rights to dividends and sale proceeds, with no single client holding more than 5% of the class.
Syndax Pharmaceuticals reported preliminary unaudited 2025 figures alongside a presentation at the 44th Annual J.P. Morgan Healthcare Conference. The company estimates U.S. net product revenue for Revuforj® (revumenib) at approximately $44 million for the fourth quarter and $125 million for the full year ended December 31, 2025. Niktimvo™ (axatilimab-csfr) generated an estimated $56 million in U.S. net product revenue for the quarter and $152 million for the full year, with Syndax to report its share of net commercial profit when it releases full-year 2025 results. The company also disclosed preliminary total cash, cash equivalents and marketable securities of about $394 million as of December 31, 2025. All figures are unaudited and subject to change as the year-end audit is completed.